Clinical Ink, a global clinical trial data and technology company, has acquired Digital Artefacts, a digital endpoint-based technology company with a modular platform for complex cognitive, behavioral and physiological data capture.
The combination of the two firms’ capabilities will reinforce Clinical Inks reputation as a trusted provider of digital source data capture and eCOA. This will further Clinical’s therapeutic-area-specific approach to study design and data certainty from source to submission.
As a result, Clinical Ink will be a partner for decentralized clinical trials with a complete digital data platform.
“Data derived from Digital Artefacts can now increase the richness of our partners’ study data through the convergence of passive and active digital assessments,” said Ed Seguine, Clinical Ink CEO. “Their wearables and sensors acumen provides instrumented data collection that complements our existing products and solutions…It continues our commitment to capture data at the source and deliver quantitative insights, empowering our customers to make real-time highly informed decisions.”
“We are very excited to join Clinical Ink and enhance the seamless data collection, cognitive and behavioral assessments, and quantitative outcomes for even the most complex studies,” added Joan Severson, co-founder, president and general manager of Digital Artefacts.